Duchenne muscular dystrophy essentials
- Duchenne muscular dystrophy, or DMD, is a genetic disorder caused by disease-causing changes in the DMD gene that lead to little or no functional dystrophin protein.
- It usually causes progressive muscle weakness beginning in early childhood. Heart muscle, breathing muscles, bones, digestion, learning, and emotional health can also be affected.
- Diagnosis is confirmed with genetic testing whenever possible. A high creatine kinase level can raise suspicion but does not identify the exact genetic change.
- Care is multidisciplinary and may include corticosteroids, physical and occupational therapy, heart and breathing surveillance, bone and nutrition care, mobility support, and mutation-specific or other disease-modifying treatments.
- Severe breathing difficulty, blue or gray color, chest pain, fainting, new irregular heartbeat, choking, or rapidly worsening weakness during an illness needs urgent or emergency care.

What Duchenne muscular dystrophy is
DMD is a progressive neuromuscular disease caused by variants in the DMD gene. This gene provides instructions for dystrophin, a protein that helps stabilize muscle cells during contraction. Without enough functional dystrophin, muscle fibers are repeatedly injured and gradually replaced by fat and scar tissue.
The DMD gene is on the X chromosome. The condition therefore most often causes severe disease in boys and men. Girls and women with one disease-causing variant are often called carriers, but some develop muscle weakness, pain, fatigue, or heart disease and need their own medical surveillance. Gender identity does not change the underlying chromosome or organ-specific care a person may need.
Becker muscular dystrophy involves the same gene but usually allows some partially functional dystrophin and has a later or more variable course. The boundary is not always obvious from age alone. Genetic findings, dystrophin function, and the clinical pattern help specialists classify a dystrophinopathy.
Early signs and motor development
Signs often appear between ages two and five. A child may walk later, fall often, have trouble running or jumping, walk on the toes, struggle with stairs, or use the hands to push up the thighs when rising from the floor. This maneuver is called a Gowers sign. Calves may look enlarged because muscle is replaced by fat and connective tissue.
Weakness generally begins in muscles around the hips and shoulders and later affects other muscle groups. A child may tire during play or need more time to keep up. Developmental or speech delay can precede obvious weakness. Motor regression, such as losing a skill that was already acquired, deserves prompt assessment.
Progression varies even within families. Most people eventually need wheeled mobility, but the age and sequence differ with genotype, treatment, complications, and other factors. Mobility equipment can conserve energy, reduce falls, protect participation, and preserve independence; it should not be framed as giving up.
Heart, breathing, and other body systems
Dystrophin is important in heart muscle. Cardiomyopathy can begin before symptoms, and rhythm disturbances may occur. Regular cardiac imaging and electrocardiographic monitoring start early. Heart-protective medicines may be recommended based on age, imaging, and specialist guidance, even when the person feels well.
Breathing muscles gradually weaken. Early effects may appear during sleep as morning headaches, restless sleep, nightmares, daytime sleepiness, reduced concentration, or difficulty lying flat. Cough can become too weak to clear mucus during a respiratory infection. Pulmonary testing, sleep assessment, assisted-cough techniques, and noninvasive ventilation can support breathing and quality of life.
Scoliosis, joint contractures, low bone density, fractures, delayed growth or puberty, excess or low weight, constipation, reflux, and swallowing problems can develop. Corticosteroids, reduced weight-bearing, and the disease itself affect bone health. Learning differences, attention-deficit symptoms, autism traits, anxiety, and depression are more common and deserve specific support rather than being attributed to motivation.
When symptoms are urgent
Call emergency services for severe breathing difficulty, blue or gray lips or skin, confusion, fainting, severe chest pain, a sustained rapid or irregular heartbeat with illness, or inability to stay awake. Tell emergency clinicians that the person has DMD and may have weak breathing muscles even if lung sounds are quiet.
Urgent assessment is needed for choking, repeated coughing with meals, suspected aspiration, a respiratory infection with weaker cough or falling oxygen compared with the person’s plan, new inability to move after a fall, severe bone pain, or possible fracture. Fractures can occur after minor trauma when bones are fragile.
A person taking long-term corticosteroids may have adrenal suppression and need a stress-dose plan during serious illness, injury, or surgery. Abruptly stopping corticosteroids can be dangerous. Carry the current emergency plan and alert information, and contact the neuromuscular team during acute illness.
How DMD is inherited
DMD is inherited in an X-linked pattern. A carrier has a chance of passing the variant in each pregnancy, but the outcome depends on which sex chromosome the child inherits. Some cases arise from a new variant, so the mother may not have the variant in a standard blood sample. Germline mosaicism can still affect recurrence risk.
Once the family’s variant is known, genetic counseling can explain testing for relatives, reproductive options, and cardiac screening for carriers. Carrier testing should use a method capable of detecting the family’s exact deletion, duplication, or small sequence change. A negative result from a limited consumer panel may not answer the question.
Genetic information can affect several relatives and can carry emotional and privacy concerns. Counseling should be factual and non-directive. No family member caused DMD through diet, activity, or something done during pregnancy.
Diagnosis and baseline assessment
A clinician may suspect DMD from motor history and examination. Creatine kinase, or CK, is often markedly elevated because damaged muscle releases the enzyme into blood. Elevated liver enzymes can actually come from muscle, so CK testing can prevent an unnecessary liver-only investigation. CK is not specific enough to confirm DMD.
Genetic testing is the preferred confirmation. Testing commonly begins with methods that detect exon deletions or duplications and continues with sequencing when needed. Identifying the variant confirms the diagnosis in most people, supports family testing, and determines whether a mutation-specific treatment might apply.
Muscle biopsy is now used less often but may be considered when genetic testing is inconclusive. Dystrophin staining and other studies can help classify disease. Baseline assessment also reviews heart function, breathing, growth, nutrition, bone health, movement, learning, behavior, and family support so care begins before complications are obvious.
Coordinated long-term care
DMD care typically involves neuromuscular specialists, primary care, cardiology, pulmonology, rehabilitation, physical and occupational therapy, orthopedics, endocrinology, nutrition, psychology, social work, and genetics. A written care plan helps coordinate surveillance, school needs, equipment, surgery, and emergencies.
Physical therapy focuses on comfortable range of motion, positioning, contracture prevention, safe activity, and energy conservation. Gentle submaximal activity can support health, while high-resistance or eccentric exercise can damage vulnerable muscle. A therapist experienced in DMD should tailor the plan rather than applying a standard strength program.
Night splints, standing devices, seating, transfer equipment, home modifications, and power mobility can support alignment and participation. Equipment should be introduced before a crisis so the person can learn it and the family can arrange access.
Corticosteroids and supportive medicines
Corticosteroid therapy can slow loss of muscle strength and function and may support heart and breathing outcomes for some people. Products and schedules have different benefits and side effects. Possible harms include weight gain, behavior or sleep changes, growth suppression, delayed puberty, high blood pressure, glucose changes, cataracts, infection risk, and weak bones.
The neuromuscular team monitors growth, blood pressure, eyes, bone health, nutrition, and endocrine effects and adjusts treatment with the family. A steroid should not be started, changed, or stopped without a plan. The person needs instructions for missed doses, vomiting, surgery, fever, and other physiologic stress.
Heart medicines, bone treatments, vaccines, bowel regimens, and respiratory therapies may be prescribed according to surveillance. Each part supports a particular risk and should be reviewed for interactions and treatment burden.
Disease-modifying and mutation-specific treatments
Some approved therapies target particular genetic mechanisms. Exon-skipping drugs apply only to variants amenable to skipping a specific exon. They do not work for every DMD variant, and approval may rely on measures of increased dystrophin with ongoing study of clinical benefit. The exact genetic report must be reviewed by a specialist.
Givinostat is a nonsteroidal oral treatment approved by the U.S. Food and Drug Administration for certain patients with DMD. It affects histone deacetylase activity and requires monitoring for blood-count changes, triglycerides, gastrointestinal effects, and other label-specific risks. Age eligibility and current prescribing information must be checked at the time of treatment.
Gene therapy indications and safety information have changed. Current FDA information limits delandistrogene moxeparvovec-rokl, sold as Elevidys, to ambulatory patients age four years and older with a confirmed DMD gene mutation. The label carries a boxed warning for serious and fatal liver injury and requires careful selection, immune and liver evaluation, corticosteroid management, and close monitoring.
Gene therapy is not a cure and is not appropriate for every person. Preexisting antibodies, liver status, mutation details, current function, infection, and other factors can affect eligibility or risk. Families should use the current FDA label and an experienced center rather than relying on an older announcement that described a broader indication.
Respiratory and cardiac protection
Pulmonary monitoring may include forced vital capacity, cough strength, oxygen and carbon dioxide assessment, and sleep studies. Air stacking, mechanical insufflation-exsufflation, and noninvasive ventilation can support ventilation and airway clearance. Oxygen alone can hide hypoventilation in a person with muscle weakness, so acute treatment should assess ventilation, not only oxygen saturation.
Cardiology follow-up often includes electrocardiograms and echocardiography or cardiac MRI. Treatment may begin before symptoms because early heart-muscle changes can be silent. New palpitations, fainting, chest pain, swelling, or reduced exercise tolerance should be reported promptly.
Before anesthesia or sedation, the team must know about DMD because certain anesthetic agents and depolarizing muscle relaxants can create serious risk. Surgery should be planned with anesthesia, cardiac, respiratory, and neuromuscular input, including postoperative cough and ventilation support.
Nutrition, bone health, and swallowing
Nutrition needs change with growth, steroid use, activity, and swallowing function. The goal is adequate nutrition without excessive restriction. Dietitians can address weight gain, low intake, constipation, reflux, vitamin D, calcium, and feeding fatigue. Sudden weight change should prompt medical review.
Bone-health care includes fracture history, vitamin status, steroid exposure, puberty, pain, and imaging when indicated. Back pain can signal vertebral fracture even without a major fall. Fracture care should preserve mobility when possible and involve clinicians familiar with DMD.
A speech-language or swallowing assessment may be needed for prolonged meals, coughing, wet voice, recurrent chest infections, or weight loss. Texture changes and feeding support are individualized. A feeding tube can supplement nutrition and medicines while allowing safe oral pleasure when appropriate; it is not a measure of failure.
School, adulthood, and quality of life
Educational assessment can identify language, reading, attention, executive-function, or social needs. School plans may address accessible transport, fatigue, extra time, emergency evacuation, bathroom access, assistive technology, and participation with peers. Academic expectations should reflect ability, not muscle strength.
Transition to adult care should begin early and include decision-making support, personal assistance, housing, education, work, relationships, sexual health, and benefits. People with DMD can direct their own lives and care. Communication devices and environmental controls can increase independence as physical needs change.
Palliative care can help with symptoms, complex choices, and family support at any stage. It can be provided alongside disease-directed treatment. Advance care planning should center the person’s goals and be revisited rather than presented as a single end-of-life conversation.
Preparing for a specialist visit
Bring the complete genetic report, current medicine doses, emergency steroid plan, equipment list, recent heart and lung results, falls or fractures, sleep symptoms, swallowing concerns, and changes in mobility. Record barriers to therapy, school, transportation, or caregiving because the team may be able to simplify or support the plan.
Ask what surveillance is due, which treatments match the exact variant and age, what benefit was shown, and which risks require monitoring. Clarify emergency breathing and steroid instructions, vaccine plans, anesthesia precautions, cardiac treatment, bone protection, and who coordinates after-hours care.
Official sources
- MedlinePlus Genetics: Duchenne and Becker Muscular Dystrophy
- Centers for Disease Control and Prevention: Types of Muscular Dystrophy
- U.S. Food and Drug Administration: Approval of givinostat for Duchenne muscular dystrophy
- FDA: New boxed warning and revised indication for Elevidys
- FDA: Elevidys product information